The UK Huntington Disease (HD) Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Huntington’s disease (HD) is an inherited condition characterized by the progressive degeneration of neurons within certain areas of the brain (e.g., basal ganglia, cerebral cortex). People with HD usually live for about 15 to 20 years after the condition begins. Signs and symptoms usually develop between ages 35 to 44 years and may include uncontrolled movements, loss of intellectual abilities, and various emotional and psychiatric problems.
Huntington’s disease is transmitted as an autosomal dominant trait. The disease results from changes (mutations) of a gene known as “huntingtin (HTT)” located on the short arm (p) of chromosome 4. In those with the disorder, the huntingtin gene contains errors in the coded “building blocks” (nucleotide bases) that make up the gene’s instructions. A brief review of the number of patients by the Huntington Disease Association in the UK indicated that approximately 6,700 individuals in the UK are currently living with HD. This means that 12.4 per 100,000 persons or 1 out of every 8,065 individuals may be affected with Huntington’s disease.
Market Growth Drivers
High unmet needs within the market present a key commercial opportunity to develop breakthrough disease-modifying therapies. The Huntington’s disease pipeline is expected to witness new developments over the next decade as several privately-held and innovation-driven pharmaceutical companies venture into the HD treatment arena. The introduction of disease-modifying drugs is poised to transform the market landscape. With ongoing research, there are increasingly significant opportunities for drug companies to develop new drugs with novel mechanisms of action.
The Huntington’s disease treatment market is expected to witness novel product launches, including the approval of several disease-modifying therapies. Current research in HD focuses on using novel treatments such as immuno-modulating therapies, gene therapy (using antisense oligonucleotides, micro RNAs (miRNA), mRNA splicing, and zinc-finger DNA binding protein).
Increasing incidence and prevalence of Huntington’s disease is one of the major key drivers of HD market growth over the forecast period. The potential role of RNA antisense technology and stem cell therapy is under active clinical investigation. Wave Life Sciences and Roche’s antisense oligonucleotides aim to target underlying disease causes and are expected to contribute significantly to market growth.
However, an increase in the cost of medical treatment, less prominent reimbursement policies, and occurrence of side effects in related currently available treatments may hamper the Huntington disease treatment market growth.